Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognostic utility of serum YKL-40 in patients with cervical cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Estimation of the celiac disease prevalence in Denmark and the diagnostic value of HLA-DQ2/DQ8

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circadian variations in plasma concentrations of cholecystokinin and gastrin in man

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Inflammation is one of the hallmarks of cancer and plays a crucial role in the development and progression. The objective of the present study was to investigate if high serum YKL-40 is related to poor prognosis in cervical cancer (CC) patients. A prospective biomarker study of 116 patients with CC (FIGO stage Ia: n = 4; Ib: n = 55; II: n = 26; III: n = 26; IV: n = 5) and 152 patients with cervical intraepithelial neoplasia (CIN). The patients received primary surgery, radiotherapy and chemotherapy according to standard guidelines during the period 2001-2004. Seventy patients died during the follow-up period (median 117 months, range 104-131). Serum concentrations of YKL-40 were measured by ELISA. Serum concentrations of YKL-40 were increased (p < .001) in CC patients (median 76 µg/L, IQR 45-148) compared to CIN patients (44 µg/L, IQR 30-61) and healthy women (41 µg/L, IQR 29-58). YKL-40 was elevated (>age-corrected 95th percentile of YKL-40 in healthy women) in 30 (26%) of the CC patients. Univariate Cox analysis demonstrated that YKL-40 (included as a log-transformed continuous variable (base 2)) was associated with recurrence-free survival (RFS) (HR = 1.48, 95% CI: 1.11-1.98, p = .008) and overall survival (OS) (HR = 1.74, 1.44-2.10, p < .0001). Multivariate Cox analysis showed that stage (II + III vs. I: HR = 2.92, 1.37-6.20, p = .005), YKL-40 (HR = 1.35, 1.06-1.73, p = .018) and age (HR = 1.56, 1.21-1.99, p = .0005) were independent prognostic variables of OS. During treatment, a 2-fold increase in YKL-40 compared to baseline level was associated with short RFS (HR = 1.87, 1.27-2.77, p = .0016) and OS (HR = 1.78, 1.26-2.50, p = .0010). Serum YKL-40 is an independent biomarker of OS in patients with cervical cancer.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Clinical and Laboratory Investigation
Vol/bind80
Udgave nummer8
Sider (fra-til)687-693
Antal sider7
ISSN0036-5513
DOI
StatusUdgivet - 1 dec. 2020

ID: 61251418